Rational Design, Synthesis, Biological Evaluation, and In Silico Study of N ‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐yl) Derivatives as EGFR Inhibitors Targeting EGFR WT , EGFR T790M , and EGFR L858R / T790M / C797S in NSCLC
Open Access
- 8 September 2026
- journal article
- research article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 108 (3) , e70390
Abstract
Non‐small cell lung cancer (NSCLC), driven by mutations in the epidermal growth factor receptor (EGFR), presents significant therapeutic challenges, particularly due to drug resistance. This study describes the design, synthesis, and evaluation of a series of novel N ‐Cinnamamide/benzamide‐(4‐(substituted phenyl)‐6‐(4‐cyclohexylphenyl)pyrimidin‐2‐yl) derivatives ( Ri–Rxii ) as EGFR inhibitors. Among these, compound Riv exhibited superior antiproliferative activity against wild‐type and mutant EGFR‐driven NSCLC cell lines, including EGFR L858R/T790M and the drug‐resistant EGFR L858R/T790M/C797S variant, with low IC 50 values and minimal cytotoxicity towards normal cell lines. Compound Riv effectively induced cell cycle arrest at the S and G2/M phases and triggered apoptosis, with 54.38% of cells undergoing apoptotic or necrotic death. Additionally, Riv exhibited strong antioxidant activity, outperforming the standard ascorbic acid in DPPH and ABTS assays, indicating its ability to reduce oxidative stress. Molecular docking and dynamic simulation studies confirmed stable binding interactions with key EGFR residues, and DFT analysis revealed favorable electronic properties. Furthermore, in silico ADMET predictions highlighted Riv 's promising pharmacokinetic and toxicity profiles, supporting its potential as a safe and effective anticancer agent. This comprehensive evaluation positions Riv as a strong candidate for overcoming drug resistance in NSCLC treatment.Keywords
Funding Information
- Indian Council of Medical Research (5/13/12/2020/NCD‐III)
- Indian Council of Medical Research (5/13/79/2020/NCD‐III)
- Indian Council of Medical Research (IIRPSG‐2024‐01‐01202)
This publication has 58 references indexed in Scilit:
- Novel pyrazole–oxadiazole–chalcone/oxime hybrids as dual EGFR/VEGFR-2 inhibitors with promising anticancer potential: a comprehensive cytotoxicity evaluation, mechanistic insights and SAR analysisMolecular Diversity, 2026
- Design, Synthesis, and Molecular Profiling of Pyrimidine‐Furan Derivatives Targeting EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S in NSCLC: In Vitro and In Silico EvaluationChemistry & Biodiversity, 2025
- Pyrazole, Pyrazoline, and Fused Pyrazole Derivatives: New Horizons in EGFR‐Targeted Anticancer AgentsChemistry & Biodiversity, 2024
- Designing Studies in Pharmaceutical and Medicinal Chemistry2023
- 2-Aminopyrimidine2023
- Nitrogen‐Containing Heterocyclic Scaffolds as EGFR Inhibitors: Design Approaches, Molecular Docking, and Structure‐Activity RelationshipsChemistrySelect, 2023
- A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapyBioorganic Chemistry, 2020
- Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducersBioorganic Chemistry, 2019
- YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M‐mutant resistance in vitro and in vivoCancer Medicine, 2018
- Eco-sustainable synthesis and biological evaluation of 2-phenyl 1,3-benzodioxole derivatives as anticancer, DNA binding and antibacterial agentsArabian Journal of Chemistry, 2016